CITIIQ
CitiIQ (http://www.citiiq.com ) has applied its novel measurement standard to 1,170 global cities as an important step toward measuring the 4,000 cities of the world with a population over 100,000.
The 1,170 cities include those with populations greater than 500,000, the world’s country capitals, and the state capitals of Brazil, India China and the USA.
“Increasingly, the health and wellbeing of people depend upon the effectiveness of their city,” says Don Simmonds, Chief Executive Officer of CitiIQ. “Municipal leaders face immense challenges and benefit greatly when comprehensive, comparable data is available to guide their decisions.”
Most cities struggle to translate disparate data into actions that can make life better for their citizens. The CitiIQ measurement system is an objective assessment of the overall health and wellbeing of a city. It converts raw data into scores out of 100 so that city elements are readily compared within a given city, or with other cities around the world.
CitiIQ uses an evidence-based methodology to score 35 essential elements, or Considerations, within five prioritized Dimensions including Basic Needs, Competitiveness, Opportunity, Livability, and Destiny. Using an intuitive online dashboard, a city’s measurements are readily available to clients through a cloud-based annual subscription.
“The CitiIQ measurement helps immensely in understanding the factors that influence a city,” says Harry Loubser, Managing Director of Unashamedly Ethical based in Cape Town, South Africa. “It's value to municipal leaders is readily apparent but the ability to compare city to city across so much of the world is a powerful advantage. We can clearly identify where best practise has been applied, but also illuminate cities with the greatest needs.”
The CitiIQ system is easy to use, economical, and effective with no need to purchase new software or abandon existing metrics. Aligned with the United Nations Sustainable Development Goals, CitiIQ provides a practical way for a city to mark progress toward SDG achievement.
City Administrators appreciate the integration of economic, environmental, social and cultural infrastructure measures reflecting how a city actually functions. The algorithm normalizes data into a comparable, holistic picture of their city’s strengths and weaknesses bringing coherence and comparability to their operations and an ability to compare with other cities.
In April 2020 CitiIQ was selected by UN-Habitat to develop a COVID-19 Readiness and Responsiveness tracking site for more than 1,000 global cities. Data was often unavailable at a city level where the real battle is fought. The scoring reflects both how ready a city was for COVID-19 and how well they are responding to the pandemic. COVID-19 data is collected daily for the 1,000 cities supporting improve responses to the pandemic. Visit: https://unhabitat.citiiq.com/ .
About CitiIQ
CitiIQ is a comprehensive system that objectively measures the overall health and wellbeing of a city. Using an intuitive online dashboard style interface, a city’s measurements are made readily available to clients through a cloud-based annual subscription.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200827005026/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Enginzyme and AGC Create Scalable Process for Key mRNA Ingredient12.1.2026 06:00:00 CET | Press release
At the mRNA Health conference in Berlin, enginzyme and AGC Inc. presented a scalable process to produce a key mRNA vaccine and therapy ingredient, N1-methylpseudouridine-5'-triphosphate (m¹ΨTP). The rapid growth of mRNA-based vaccines and therapeutics has driven significant demand for modified nucleotides like m¹ΨTP, which enhances mRNA stability and expression, while reducing immunogenicity. Enginzyme is a deep-tech company delivering optimized biomanufacturing solutions through cell-free enzyme engineering technology. AGC Inc. is a leading global player in fields spanning from architectural glass to chemicals and life science. AGC Inc. provides services in a wide range of life science fields, from synthetic pharmaceuticals and agrochemicals, to biopharmaceuticals and leading-edge cell and gene therapies, as well as messenger RNAs. The presentation in November detailed the latest collaboration between the companies, with a focus on the biomanufacturing of nucleotides for mRNA therapy,
Ant International Partners with Google’s Universal Commerce Protocol to Expand AI Capabilities12.1.2026 02:15:00 CET | Press release
Ant International, a leading global payment, digitisation, and financial technology provider, is collaborating on the launch of Google’s Universal Commerce Protocol (UCP), a new open standard for agentic commerce that works across the entire shopping journey — from discovery and buying to post-purchase support. UCP establishes a common language for agents and systems to operate together across consumer surfaces, businesses, and payment providers to enable commerce. So instead of requiring unique connections for every individual agent, UCP enables all agents to interact easily. UCP is built to work across verticals and is compatible with existing industry protocols like Agent2Agent (A2A), Agent Payments Protocol (AP2), and Model Context Protocol (MCP). “For agentic commerce to scale, it’s critical for the industry to align on a common set of standards. We are proud to have Ant International endorse the Universal Commerce Protocol as the foundation for that future,” said Ashish Gupta, VP
Torq Secures $140M Series D at $1.2B Valuation to Lead the AI SOC and Agentic AI Era11.1.2026 17:59:00 CET | Press release
Fueled by Massive Customer Adoption of AI Agents, Torq Scales the World’s First True AI SOC Platform and Accelerates Expansion into the U.S. Federal Market Torq, the established Agentic AI security operations pioneer, today announced it has closed a massive $140 million Series D funding round, propelling its valuation to $1.2 billion and total funding to $332M. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260112510774/en/ Led by Merlin Ventures—a leading cybersecurity fund renowned for its deep access to the U.S. commercial and Public Sector markets—with participation from all existing investors, including Evolution Equity Partners, Notable Capital, Bessemer Venture Partners, Insight Ventures Partners, and Greenfield Partners, this capital injection is a definitive investment in the future of security. Torq is driving the industry’s critical shift: the complete transformation of the Security Operations Center (SOC) through
Andersen udvider sine kompetencer med tilføjelsen af Scimitar9.1.2026 21:44:00 CET | Pressemeddelelse
Andersen Consulting har indgået en samarbejdsaftale med Scimitar, der er et firma med fokus på at accelerere innovation i biovidenskabsbranchen. Scimitar, der har hovedkvarter i USA, et førende konsulenthus inden for strategieksekvering for biovidenskabsbranchen. Virksomheden er specialiseret i design af driftsmodeller, digital transformation og organisatorisk forandring. Scimitar samarbejder med medicinal- og biotech-virksomheder om at accelerere innovation, styrke den driftsmæssige eksekvering og sikre compliance gennem hele produkters livscyklus. Deres praktiske og samarbejdsorienterede tilgang sikrer løsninger, der ikke blot er formålstjenlige, men også skalerbare. "Virksomheder inden for biovidenskabsbranchen befinder sig i en tid med hurtige videnskabelige fremskridt, stigende regulatorisk kompleksitet og et voksende behov for operationel agilitet, samtidig med at de holdes op mod de højeste standarder for patientsikkerhed og dataintegritet," udtaler Ramy Khalil, CEO i Scimitar.
Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 13:00:00 CET | Press release
Expanded collaboration builds on Acepodia and Biocytogen’s recent co-development efforts to evaluate selected bispecific antibody and dual-payload ADC programs Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreem
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom